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SUMMARY
In February 2012, an outbreak of respiratory illness occurred on the cruise ship MSC Armonia in Brazil. A 31-year-old female 
crew member was hospitalized with respiratory failure and subsequently died. To study the etiology of the respiratory illness, tissue 
taken at necropsy from the deceased woman and respiratory specimens from thirteen passengers and crew members with respiratory 
symptoms were analyzed. Influenza real-time RT-PCR assays were performed, and the full-length hemagglutinin (HA) gene of influenza-
positive samples was sequenced. Influenza B virus was detected in samples from seven of the individuals, suggesting that it was the 
cause of this respiratory illness outbreak. The sequence analysis of the HA gene indicated that the virus was closely related to the B/
Brisbane/60/2008-like virus, Victoria lineage, a virus contained in the 2011-12 influenza vaccine for the Southern Hemisphere. Since 
the recommended composition of the influenza vaccine for use during the 2013 season changed, an intensive surveillance of viruses 
circulating worldwide is crucial. Molecular analysis is an important tool to characterize the pathogen responsible for an outbreak such 
as this. In addition, laboratory disease surveillance contributes to the control measures for vaccine-preventable influenza.
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INTRODUCTION
Cruise ship holidays are increasing in popularity worldwide. In 
Brazil, since the 2004-05 season, there has been a considerable increase 
in both the number of ships and in the number of routes. In the 2010-11 
season along the Brazilian coast, there were approximately 800,000 
cruise passengers, including 100,000 foreigners, traveling on twenty 
cruise ships1. The nature of the cruise ship environment - enclosed and 
semi-enclosed compartments - may facilitate rapid transmission of 
infectious agents among passengers and crew members. Influenza viruses 
can easily spread when introduced into confined, crowded environments, 
and outbreaks of disease may accompany the expected increase in these 
leisure activities9. Summer season influenza outbreaks among passengers 
and crew members on cruise ships suggest that traveling in large groups 
can pose a risk for exposure to influenza viruses, even when the travel is 
in regions where influenza is not in seasonal circulation4.
Influenza outbreaks have been previously reported on cruise 
ships in Australia3,21, Canada and the USA10,20. To our knowledge, our 
investigation is the first characterization of an influenza virus outbreak 
onboard a cruise ship on the Brazilian coast.
On 17 February 2012, the Epidemiological Surveillance Centers 
of the city of Santos and the state of São Paulo (CVE) reported to the 
Brazilian Ministry of Health the death of a 31-year-old female crew 
member from the cruise ship MSC Armonia (MSC Cruzeiros Ltda) 
during a summer season in Brazil. The crew member presented with 
acute respiratory infection, and on 15 February 2012 was admitted 
to the intensive therapy unit with respiratory failure and died11. After 
interviewing the cruise ship’s physicians and health care providers of 
the cities of Santos and Guarujá, thirteen more cases of passengers 
and crew members with symptoms of an influenza-like syndrome were 
identified11. Facing a clinical diagnosis of influenza-like illness (ILI), 
respiratory samples were collected and sent to the Institute Adolfo Lutz 
for investigation. Our study was conducted to identify the etiology of the 
respiratory illness outbreak and to perform the molecular characterization 
of the pathogen.
STUDY DESIGN
1. Clinical specimens: Fourteen respiratory specimens (throat and/or 
nasopharyngeal swabs, nasopharyngeal aspirate and tracheal secretion) 
were collected from the thirteen passengers and crew members identified 
by the cruise ship’s physicians and health care providers of the cities of 
Santos and Guarujá and sent to the Adolfo Lutz Institute. Individuals 
with respiratory symptoms such as a fever, cough and sore throat of less 
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than seven days duration were eligible for inclusion in this study. Tissue 
necropsy (lung) from the fatal case was also analyzed. The specimens 
were obtained from individuals of all ages and genders. Samples were 
received on wet ice and held at 4 °C prior to processing within twenty-
four hours of receipt.
2. RNA extraction: Total viral RNA was automatically extracted from 
200 µL aliquot of respiratory sample and eluted in 70 µL using a VX viral 
DNA/RNA extraction kit (QIAxtractor® virus reagent and a QIAxtractor 
instrument [Qiagen, CA, USA]). RNA from tissue necropsy was manually 
extracted from 3 mm3 of tissue and eluted in 50 µL using a QIAamp 
RNA blood mini kit (Qiagen, CA, USA). All procedures were performed 
according to the manufacturer’s instructions prior to PCR analysis.
3. Real time RT-PCR Influenza Panel: Samples were analyzed 
using a standard testing algorithm that included the use of a real-time 
RT-PCR (rRT-PCR) assay to verify influenza viruses23. The Influenza 
Panel includes oligonucleotide primer and probe sets to detect influenza 
A(H1N1)pdm09, A(H1N1), A(H3N2) and influenza B viruses. Sequence 
information for rRT-PCR primers and probes was provided by the Centers 
for Disease Control and Prevention, Influenza Division (CDC, USA). The 
assays were optimized using an Invitrogen SuperScript® III Platinum 
One-Step quantitative RT-PCR kit (Life Technologies Corporation, SP, 
Brazil) and a Roche Light Cycler® 480 real-time PCR system (Roche 
Diagnostics, SP, Brazil).
4. Sequencing analysis: The full-length hemagglutinin (HA) gene 
was amplified by RT-PCR and sequenced based on the protocol from the 
World Health Organization (WHO)22. Sequence information for primers 
was provided by the Influenza Division at the CDC. RT-PCR products were 
directly sequenced using the ABI PRISM® BigDye™ Terminators Cycle 
Sequencing Ready Reaction (Applied Biosystems, CA, USA) with an ABI 
3130 Genetic Analyzer (Applied Biosystems, CA, USA). All nucleotide 
sequences obtained were edited and aligned using Sequencher 4.7 (Gene 
Codes Corporation, MI, USA) and Bioedit 7.08, respectively. Phylogenetic 
and molecular evolutionary analyses were conducted using MEGA 
version 519. A phylogenetic tree was constructed with the neighbor-joining 
method, bootstrapped with 1000 replicates. Sequences were compared 
with a corresponding panel of representative global sequences and vaccine 
strain for phylogenetic association and polymorphism identification. 
Representative strains were added to GenBank under accession numbers: 
JN872376-872404, HM628690-91, JX679215, KC291188-89.
RESULTS
Influenza B virus strains were identified in seven passengers and 
crew members (54%) from a total of thirteen investigated (Table 1). 
For the crew member who presented respiratory failure and died, both 
respiratory specimens and lung tissue were analyzed and influenza B 
virus was detected. All the other individuals were hospitalized; although 
none experienced respiratory failure, all required observation and were 
submitted to oseltamivir antiviral treatment. 
Based on the available information about the patients’ vaccination 
status, there was no statistically significant difference between the positive 
or negative result for influenza B viruses of vaccinated and non-vaccinated 
patients (Table 1).
The complete HA gene of nine influenza B virus strains from the 
seven positive individuals was sequenced and compared phylogenetically. 
Table 1
Analysis of passengers and crew members who presented respiratory symptoms by rRT-PCR Influenza Panel
Patients Samples Gender Ages Collection date Symptoms date Samples C
T 
valuesa Results Influenza Vaccine
10944 16/02/12 12/02/12 Tissue 23 Influenza B
1 9-1089 F 30 16/02/12 12/02/12 TS 18 Influenza B No
9-1090 16/02/12 12/02/12 RS 22 Influenza B
2 10968 F 30 17/02/12 15/02/12 RS 33 Influenza B Yes
3 10969 M 27 17/02/12 14/02/12 RS 31 Influenza B UN
4 10970 M 23 17/02/12 15/02/12 RS 26 Influenza B No
5 10972 F 24 17/02/12 15/02/12 RS 22 Influenza B Yes
6 10976 M 23 18/02/12 15/02/12 RS 26 Influenza B No
7 10977 M 31 18/02/12 16/02/12 RS 28 Influenza B UN
8 10971 M 23 17/02/12 12/02/12 RS - Negative Yes
9 10973 F 37 18/02/12 13/02/12 RS - Negative No
10 10974 F 12 18/02/12 17/02/12 RS - Negative UN
11 10975 M 10 18/02/12 18/02/12 RS - Negative Yes
12 10978 F 31 18/02/12 17/02/12 RS - Negative No
13 10979 M 24 19/02/12 17/02/12 RS - Negative No
RS = respiratory secretion (throat and/or nasopharyngeal swabs and nasopharyngeal aspirate); TS = tracheal secretion; Tissue necropsy = lung. aC
T 
= threshold cycle 
value for rRT-PCR Influenza B assay. UN = uninformed
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All strains were genetically characterized as influenza B viruses 
belonging to the Victoria lineage. Sequence analysis showed the closest 
similarity (99.2%) to the HA of vaccine strain B/Brisbane/60/2008, the 
influenza B virus lineage circulating in state of Sao Paulo during 2012 
influenza season. The strains were also similar to other influenza B 
strains isolated in our laboratory from patients with ILI and severe acute 
respiratory infection (SARI) at about the same period. 
Results shown in Fig. 1 revealed that all strains from the cruise ship’s 
outbreak formed only one branch in the phylogenetic tree and clustered 
very closely to B/Brisbane/60/2008. Considering the strains isolated 
during January 2010 to February 2012, both the B/Victoria/2/87 and the 
B/Yamagata/16/88 lineages circulated. However, the Victoria lineage was 
more prevalent than the Yamagata lineage, with 34 versus 11 strains, 
respectively. The B-Victoria lineage predominated during the 2011-12 
influenza seasons (32/33). The majority of influenza B virus strains 
identified by our surveillance system shared an amino acid substitution 
at positions I146V (30/45) and L58P (11/43) in the HA compared with 
the vaccine virus.
DISCUSSION
On 20 February 2012, the Adolfo Lutz Institute reported that the 
influenza B virus was detected in seven individuals, implicating the 
influenza B virus as the cause of a respiratory illness outbreak onboard 
the cruise ship. Sequence analysis of the HA gene of influenza B strains 
indicated that the viruses were closely related to a B/Brisbane/60/2008-
like virus belonging to the Victoria lineage, the vaccine virus for the 
2011-12 southern hemisphere influenza seasons. Although the amino acid 
changes at I146V and L58P positions, neither substitution has a marked 
affect on the antigenicity of the viruses7. No significant differences were 
detected among the amino acid residues within the HA receptor binding 
sites of influenza B viruses. 
Although influenza virus outbreaks on cruise ships have not been 
frequently reported, they represent a great public health concern. In 2000, 
an outbreak of influenza B was described in Northern Europe, with a total 
of 64 (13%) crew members and 54 (4%) passengers identified with Acute 
Respiratory Infection (ARI)4. BROTHERTON et al.3 also reported an 
outbreak on a cruise ship sailing between Australia and New Caledonia 
involving 37% of the passengers; both influenza A and B viruses were 
circulating on the ship.
Influenza viruses are easily spread by droplets and aerosol produced 
by an infected person; semi-enclosed environments can facilitate the 
transmission and are difficult to control. The cruise ship MSC Armonia 
travelled for three nights along the Brazilian coast (Santos/Ilha Grande/
Angra dos Reis/Ilhabela/Santos) and carried approximately 2,000 
passengers and 800 crew members. They are from different regions, 
intermingle for extended periods in the same compartments and, 
after leaving the cruise, travelers disperse and may spread acquired 
infections. These facts highlight the great potential of travel in the 
rapid dissemination and global spread of new influenza viruses. 
Specific management to control the outbreak should include: (1) early 
identification and isolation of crew members and passengers with ILI; 
(2) implementation of good respiratory hygiene and cough etiquette 
(wearing protective masks or respirators, washing hands with soap and 
water, covering mouth and nose with a tissue and discarding it in the trash 
after use); (3) use of influenza antiviral medications for the treatment of 
persons with suspected or confirmed influenza; and (3) use of antiviral 
chemoprophylaxis on exposed persons12. 
Moreover, to decrease the exposure risk to influenza viruses, people 
should be advised that pre-existing major medical conditions (diabetes, 
chronic lung diseases, immunodeficiency) can increase the likelihood of 
illness. Travelers with a high risk of complications and all crew members 
should consider getting an influenza vaccination before travel. The CDC 
recommends a yearly influenza vaccine as the first and most important 
step in protecting against influenza viruses. People taking a summer cruise 
who were vaccinated during the previous season are still protected and 
do not need to get vaccinated again until the following influenza season. 
Fig. 1 - Phylogenetic tree of a full-length HA gene of influenza B sequences. Tree was 
constructed by neighbor-joining method (Kimura 2-parameter) using MEGA version 5. 
Numbers at the nodes indicate the bootstrap confidence levels. Reference strains are labeled 
with a square (); () black circle = sequences of passengers and crew members.
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However, people who have not been vaccinated during the previous 
season and who plan to travel during the summer should get vaccinated6. 
It is important to get vaccinated at least two weeks prior to the cruise, as 
it takes about two weeks for protective antibodies to develop6.
Two antigenically and genetically distinct lineages of influenza B 
viruses, represented by the reference strains B/Victoria/2/87 and B/
Yamagata/16/88, have co-circulated in humans since at least 198317. In 
Brazil, surveillance of the influenza B virus over a period of 12 years 
demonstrated the pattern of circulation of the two influenza B/lineages. 
The influenza B/Victoria lineage reemerged during the 2002 influenza 
season and predominated during the 2003, 2004, 2007, 2010, 2011 and 
early 2012 influenza seasons. In contrast, the co-circulation of the two 
influenza B/lineages was detected during the 2002, 2005, 2006 and 2008 
influenza seasons15. So far, according to WHO24,25, the 2011-12 influenza 
vaccines used are a good match for the strain found in the outbreak, 
meaning it elicits antibodies for the viruses that are actually circulating. 
Early data from the CDC5 suggests that this year’s vaccine is about 
60% effective. To our knowledge, based on the standardized written 
questionnaire for the systematic recording of each patient’s demographic 
and clinical characteristics (according to the clinical form of the National 
Influenza Surveillance Network), the fatal case did not receive an 
influenza vaccination. It is important to emphasize that the following 
recommended groups get an influenza vaccination: all persons who (1) 
are aged six months through two years; (2) are aged 60 years and older; 
(3) have chronic pulmonary, cardiovascular, renal, hepatic, neurologic, 
hematologic, or metabolic disorders; (4) are immunosuppressed; (5) are 
or will be pregnant during the influenza season; (6) are Native American 
Indians; (7) are morbidly obese; (8) are health-care personnel; and (9) are 
exposed to a prison population13. According to the National Immunization 
Program, an increase in the influenza vaccine coverage has been noticed 
in Brazil: 84% (2011), 86% (2012) and 92% (2013), surpassing the initial 
goal of 80% vaccine coverage14.
The vaccine strain composition for influenza B was changed to the B/
Yamagata-like virus for use in the 2012-13 influenza season in both the 
northern and southern hemispheres. Influenza vaccines administered in 
most countries over the past five years have included only a B/Victoria-
like virus; as a result, a significant proportion of the world population, 
especially including young children, has not had the exposure to those 
viruses to develop natural immunity. Immunization against B virus strains 
of one lineage provides limited cross-protection against strains in the 
other lineage2. Because of this, and the difficulty of predicting which 
B virus lineage will predominate during a given season, inclusion of a 
second influenza B vaccine virus strain in seasonal influenza vaccines 
has been proposed. A recent analysis indicates that the impact of such 
a quadrivalent vaccine could result in a modest reduction in influenza-
associated outcomes, depending upon adequate vaccine supply, coverage, 
effectiveness and the incidence of influenza associated with the two 
B lineages16. Thus, it is crucial to have an intensive surveillance of 
circulating viruses worldwide. The rRT-PCR Influenza Panel served as 
an effective emergency tool for the rapid detection of an outbreak and 
pandemic of the virus in many countries, and was essential for emergency 
response implementation18. Laboratory disease surveillance using rapid 
viral diagnostic testing contributes to the control measures for influenza, 
a vaccine-preventable disease. In addition, molecular analysis is a very 
important tool to characterize the pathogen responsible for the outbreak.
RESUMO
Caracterização molecular de surto de vírus influenza B em 
cruzeiro marítimo no Brasil 2012
Em fevereiro de 2012, durante a temporada de verão no Brasil, 
um surto de doença respiratória ocorreu no navio de cruzeiro MSC 
Armonia. Mulher de 31 anos, membro da tripulação, foi internada 
com insuficiência respiratória e morreu. Com o objetivo de estudar a 
etiologia da doença foram investigadas necrópsia de tecido do caso fatal 
e secreções respiratórias de 13 passageiros e membros da tripulação com 
sintomas respiratórios. O teste de influenza por RT-PCR em tempo real 
foi realizado e o gene completo da hemaglutinina (HA) das amostras 
positivas foi sequenciado. O vírus influenza B foi detectado em sete 
indivíduos, sugerindo-o como a causa do surto de doença respiratória a 
bordo do navio. A análise da sequência do gene da HA indicou que os 
vírus estão fortemente relacionados com o vírus B/Brisbane/60/2008, 
linhagem Victoria, componente da vacina de influenza para 2011-2012 
no hemisfério sul. Uma vez que a composição da vacina foi alterada para 
uso na temporada de 2012-2013, é essencial a vigilância ativa dos vírus 
circulantes em todo o mundo. A análise molecular é uma ferramenta 
importante para caracterização do patógeno responsável pelo surto. Além 
disso, a vigilância de doenças baseada em dados laboratoriais contribui 
para as medidas de controle da influenza, uma doença imunoprevinível.
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